Myostatin (GDF-8) as a key factor linking muscle mass and bone structure
- PMID: 20190380
- PMCID: PMC3753581
Myostatin (GDF-8) as a key factor linking muscle mass and bone structure
Abstract
Myostatin (GDF-8) is a member of the transforming growth factor-beta (TGF-beta) superfamily that is highly expressed in skeletal muscle, and myostatin loss-of-function leads to doubling of skeletal muscle mass. Myostatin-deficient mice have been used as a model for studying muscle-bone interactions, and here we review the skeletal phenotype associated with altered myostatin signaling. It is now known that myostatin is a key regulator of mesenchymal stem cell proliferation and differentiation, and mice lacking the myostatin gene show decreased body fat and a generalized increase in bone density and strength. The increase in bone density is observed in most anatomical regions, including the limbs, spine, and jaw, and myostatin inhibitors have been observed to significantly increase bone formation. Myostatin is also expressed in the early phases of fracture healing, and myostatin deficiency leads to increased fracture callus size and strength. Together, these data suggest that myostatin has direct effects on the proliferation and differentiation of osteoprogenitor cells, and that myostatin antagonists and inhibitors are likely to enhance both muscle mass and bone strength.
Figures
Similar articles
-
Bone mineral content and density in the humerus of adult myostatin-deficient mice.Calcif Tissue Int. 2002 Jul;71(1):63-8. doi: 10.1007/s00223-001-1109-8. Epub 2002 Jun 13. Calcif Tissue Int. 2002. PMID: 12060865
-
Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.Bone. 2009 Jan;44(1):17-23. doi: 10.1016/j.bone.2008.08.126. Epub 2008 Sep 13. Bone. 2009. PMID: 18852073 Free PMC article.
-
Increased muscle mass with myostatin deficiency improves gains in bone strength with exercise.J Bone Miner Res. 2006 Mar;21(3):477-83. doi: 10.1359/JBMR.051203. Epub 2005 Dec 5. J Bone Miner Res. 2006. PMID: 16491296
-
Transforming growth factor-beta and myostatin signaling in skeletal muscle.J Appl Physiol (1985). 2008 Mar;104(3):579-87. doi: 10.1152/japplphysiol.01091.2007. Epub 2007 Nov 21. J Appl Physiol (1985). 2008. PMID: 18032576 Review.
-
Myostatin: a modulator of skeletal-muscle stem cells.Biochem Soc Trans. 2005 Dec;33(Pt 6):1513-7. doi: 10.1042/BST0331513. Biochem Soc Trans. 2005. PMID: 16246158 Review.
Cited by
-
Formoterol treatment downregulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats.Oncol Lett. 2012 Jan;3(1):185-189. doi: 10.3892/ol.2011.442. Epub 2011 Oct 13. Oncol Lett. 2012. PMID: 22740878 Free PMC article.
-
Active-resisted stance modulates regional bone mineral density in humans with spinal cord injury.J Spinal Cord Med. 2013 May;36(3):191-9. doi: 10.1179/2045772313Y.0000000092. J Spinal Cord Med. 2013. PMID: 23809588 Free PMC article. Clinical Trial.
-
Common variants at CDKAL1 and KLF9 are associated with body mass index in east Asian populations.Nat Genet. 2012 Feb 19;44(3):302-6. doi: 10.1038/ng.1086. Nat Genet. 2012. PMID: 22344221 Free PMC article.
-
The Role of Systemic Inflammation in Cancer-Associated Muscle Wasting and Rationale for Exercise as a Therapeutic Intervention.JCSM Clin Rep. 2018 Jul-Dec;3(2):e00065. JCSM Clin Rep. 2018. PMID: 31134216 Free PMC article.
-
'Double-muscling' and pelvic tilt phenomena in rabbits with the cystine-knot motif deficiency of myostatin on exon 3.Biosci Rep. 2019 May 21;39(5):BSR20190207. doi: 10.1042/BSR20190207. Print 2019 May 31. Biosci Rep. 2019. PMID: 31072915 Free PMC article.
References
-
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997 May 1;387(6628):83–90. - PubMed
-
- Lee SJ. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 2004;20:61–86. - PubMed
-
- Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004 Jun 24;350(26):2682–2688. - PubMed
-
- Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Jun;4(2):157–166. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous